Synonyms: Klrc1, NKG2A
Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.
Shimon Sakaguchi
Nature Communications 2025,16, Article number:1325
David Baker
Dev Cell 2023, 58(20):2163-2180.e9.
David Julius
Cell 2017, 185-198.e16
Michael Houghton
Cell Chem Biol, 2020, 27(7):780-792.e5
Charles M. Rice
Cell 2018, 172(3):423-438.e25
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Name | Citation | CD38 | CD45 | CD39 | CD88 | CD73 | Others |
|---|---|---|---|---|---|---|---|
| RBN013209 | 0 | ||||||
| MK-0159 | 0 | ||||||
| CD38 inhibitor 1 (compound 78c) | 7 | ||||||
| AB680 | 1 | ||||||
| NQ301 | 1 | TXA2 receptor | |||||
| SodiuM Metatungstate | 3 | ||||||
| PMX-53 | 3 | ||||||
| LY-3475070 | 2 |
| Description |
Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.
|
References |
|---|
| CAS No. | 1228763-95-8 |
|---|---|
| Molecular Weight | 150 kDa |
| Isotype | Human IgG4-Kappa |
| Application | Monalizumab (Anti-Human CD159a) |
| Purification | Protein G |
| Sterility | 0.2 μM filtered |
| Formulation | PBS Buffer, PH 7.4 |
| Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT05061550 | RECRUITING | Drug: Durvalumab|Drug: Oleclumab|Drug: Monalizumab|Drug: Dat | Non-small Cell Lung Cancer | AstraZeneca | 2022-04-14 | PHASE2 |
| NCT05903092 | RECRUITING | Drug: Durvalumab|Drug: Monalizumab|Drug: Carboplatin or Cisp | Small Cell Lung Cancer; SCLC; Extensive Stage Small Cell Lung Cancer; Limited Stage Small-Cell Lung Cancer | Hirva Mamdani | 2023-09-26 | PHASE2 |
| NCT06769126 | RECRUITING | Drug: Ceralasertib|Drug: Etoposide|Drug: Platinum Compound|D | Extensive Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma, A Subtype; Lung Small Cell Carcinoma, I Subtype; Lung Small Cell Carcinoma, N Subtype; Lung Small Cell Carcinoma, P Subtype | SWOG Cancer Research Network | 2025-11-06 | PHASE2 |
| NCT06152523 | WITHDRAWN | Drug: Monalizumab/MEDI5257 | MSI; dMMR Colorectal Cancer | Assistance Publique - Hôpitaux de Paris | 2023-12 | PHASE2 |
| NCT07146230 | NOT_YET_RECRUITING | Drug: Durvalumab|Drug: Monalizumab|Drug: Oleclumab | Non-small Cell Lung Cancer | Montefiore Medical Center | 2026-09 | PHASE2 |
| NCT06503614 | RECRUITING | Drug: Durvalumab|Drug: Monalizumab | Non-muscle Invasive Bladder Cancer; Non-Muscle Invasive Bladder Urothelial Carcinoma | John Sfakianos | 2025-02-24 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-08-21)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.